TB-500 10mg A synthetic fragment of Thymosin Beta-4 corresponding to the actin-binding domain, extensively studied for its role in cardiac angiogenesis, soft tissue healing, and corneal regeneration
rapid clearance yet prolonged biological effects TB-500 plasma half-life : Longer than BPC-157
It is classified as an unapproved new drug , meaning it cannot be legally marketed, sold, or prescribed as a therapeutic agent
Local sites can become tender with repeated daily injection over weeks
Short-term side effects include flushing (related to vasodilation), nausea (mitigated by maintaining appropriate hydration status), brief headache, or dizziness/lightheadedness
In addition to its benefits for the musculoskeletal system, BPC-157 protects the digestive tract